Secondary hypoparathyroidism due to impaired parathormon secretion
diseaseOn this page
Summary
Secondary hypoparathyroidism due to impaired parathormon secretion (MONDO:0015357) is a disease. A subtype of hypoparathyroidism — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-5 / 10 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 26
Clinical features
Epidemiology
Prevalence records
3 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-5 / 10 000 | 24.75 | Europe | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.8 | Denmark | Validated |
| Annual incidence | 1-9 / 100 000 | 1.7 | Spain | Validated |
Signs & symptoms
Clinical features (HPO)
26 HPO clinical features (Orphanet curated; top 26 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0000828 | Abnormality of the parathyroid gland | Very frequent (80-99%) |
| HP:0000121 | Nephrocalcinosis | Frequent (30-79%) |
| HP:0000829 | Hypoparathyroidism | Frequent (30-79%) |
| HP:0002135 | Basal ganglia calcification | Frequent (30-79%) |
| HP:0002901 | Hypocalcemia | Frequent (30-79%) |
| HP:0002905 | Hyperphosphatemia | Frequent (30-79%) |
| HP:0012378 | Fatigue | Frequent (30-79%) |
| HP:0031817 | Decreased circulating parathyroid hormone level | Frequent (30-79%) |
| HP:0000716 | Depression | Occasional (5-29%) |
| HP:0000739 | Anxiety | Occasional (5-29%) |
| HP:0001250 | Seizure | Occasional (5-29%) |
| HP:0002150 | Hypercalciuria | Occasional (5-29%) |
| HP:0002380 | Fasciculations | Occasional (5-29%) |
| HP:0002748 | Rickets | Occasional (5-29%) |
| HP:0002749 | Osteomalacia | Occasional (5-29%) |
| HP:0003394 | Muscle spasm | Occasional (5-29%) |
| HP:0007302 | Bipolar affective disorder | Occasional (5-29%) |
| HP:0007787 | Posterior subcapsular cataract | Occasional (5-29%) |
| HP:0011675 | Arrhythmia | Occasional (5-29%) |
| HP:0025425 | Laryngospasm | Occasional (5-29%) |
| HP:0031006 | Acroparesthesia | Occasional (5-29%) |
| HP:0031990 | Chvostek sign | Occasional (5-29%) |
| HP:0033630 | Brain fog | Occasional (5-29%) |
| HP:0033748 | Hypoesthesia | Occasional (5-29%) |
| HP:4000007 | Bronchoconstriction | Occasional (5-29%) |
| HP:6000919 | Trousseau sign | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | secondary hypoparathyroidism due to impaired parathormon secretion |
| Mondo ID | MONDO:0015357 |
| Orphanet | 140286 |
| ICD-11 | 1229357339 |
| UMLS | C4305428 |
| MedGen | 931097 |
| GARD | 0019922 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of hypoparathyroidism. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › endocrine system disorder › parathyroid gland disorder › hypoparathyroidism › secondary hypoparathyroidism due to impaired parathormon secretion
Related subtypes (2): hereditary hypoparathyroidism, autoimmune hypoparathyroidism
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.